<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581607</url>
  </required_header>
  <id_info>
    <org_study_id>BOSAPAH-1</org_study_id>
    <secondary_id>7-3-22-1</secondary_id>
    <nct_id>NCT00581607</nct_id>
  </id_info>
  <brief_title>Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
  <acronym>BOSAPAH</acronym>
  <official_title>Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary
      hypertension is a condition where the right side of the heart has to push the blood though
      the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for
      the heart to pump the blood through the lungs to the left side of the body. If the blood can
      not get through the lungs, it can not get pumped through the rest of the body. This leads to
      weakness and shortness of breath. This type of hypertension does not usually respond to
      regular blood pressure medicines. The purpose of this study is to determine if bosentan
      (Tracleer) will help sarcoidosis associated pulmonary hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in 2:1 manner to receive either bosentan or placebo for 16 weeks.
      After 16 weeks, there will be an additional 32 weeks of an open label extension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in six minute walk distance</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary hemodynamics</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life with therapy</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>62.5 mg bid for 4 weeks, then 125 mg bid</description>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <other_name>Tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>drug given for 16 weeks</description>
    <arm_group_label>Bosentan for 16 weeks</arm_group_label>
    <other_name>tracleer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with known sarcoidosis 21.

          -  Age 18 or greater

          -  Patients with documented pulmonary hypertension with a PA mean &gt; 25 mm Hg as measured
             by cardiac catheterization within six months of entry into the study. Pulmonary artery
             occluding pressure and or left ventricular end diastolic pressure must be less than 15
             mm Hg.

          -  Patients with WHO class II or III

          -  Six minute walk distance of between 100 to 500 meters

          -  Patients on stable immunotherapy for their sarcoidosis, including prednisone,
             methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or
             infliximab

          -  Patients able to provide written consent

        Exclusion Criteria:

          -  Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n
             the prior 28 days. Patients on stable dose of calcium channel blocker for more than 1
             month prior to right heart catheterization can be continued on the calcium channel
             blocker.

          -  Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%

          -  Patients with World Health Organization (WHO) class IV status.

          -  Patients who are pregnant or breast feeding

          -  Patients with significant left ventricular dysfunction with a left ventricular
             ejection fraction of less than 35%

          -  Cardiac index &lt; 2.0 liters and/or right atrial pressure &gt;15 mm Hg

          -  Significant liver dysfunction not due to sarcoidosis.

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study.

          -  Patients unable to perform the 6 minute walk study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 30, 2018</submitted>
    <returned>February 27, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

